GT201000107A - Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado. - Google Patents

Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado.

Info

Publication number
GT201000107A
GT201000107A GT201000107A GT201000107A GT201000107A GT 201000107 A GT201000107 A GT 201000107A GT 201000107 A GT201000107 A GT 201000107A GT 201000107 A GT201000107 A GT 201000107A GT 201000107 A GT201000107 A GT 201000107A
Authority
GT
Guatemala
Prior art keywords
inhaled
inhibitor
corticoesteroid
pde
compositions including
Prior art date
Application number
GT201000107A
Other languages
English (en)
Inventor
Thibert Roch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000107A publication Critical patent/GT201000107A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPOSICIONES PARA INHALACIÓN QUE COMPRENDEN ÁCIDO MONTELUKAST Y UN SEGUNDO INGREDIENTE ACTIVO SELECCIONADO DE UN INHIBIDOR PDE4 Y UN CORTICOSTEROIDE INHALADO POR LO QUE LA PRESENTE ES DE UTILIDAD EN TRASTORNOS RESPIRATORIOS.
GT201000107A 2007-10-25 2010-04-19 Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado. GT201000107A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
GT201000107A true GT201000107A (es) 2012-03-13

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000107A GT201000107A (es) 2007-10-25 2010-04-19 Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado.

Country Status (19)

Country Link
US (1) US20100210611A1 (es)
EP (1) EP2211863A4 (es)
JP (1) JP2011500731A (es)
KR (1) KR20100072295A (es)
CN (1) CN101909626A (es)
AU (1) AU2008316283A1 (es)
CA (1) CA2701956A1 (es)
CO (1) CO6270213A2 (es)
CR (1) CR11439A (es)
DO (1) DOP2010000122A (es)
GT (1) GT201000107A (es)
IL (1) IL205182A0 (es)
MA (1) MA33705B1 (es)
MX (1) MX2010004529A (es)
NI (1) NI201000069A (es)
NZ (1) NZ584876A (es)
RU (1) RU2470639C2 (es)
WO (1) WO2009052624A1 (es)
ZA (1) ZA201002562B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) * 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
CA2427814C (en) * 2000-11-07 2009-06-02 Merck & Co., Inc. A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
HUP0500078A3 (en) * 2001-09-19 2010-07-28 Nycomed Gmbh Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
WO2005025578A1 (en) * 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
JP2007508271A (ja) * 2003-10-10 2007-04-05 シントン・ベスローテン・フェンノートシャップ 固体状態のモンテルカスト
PT1713471E (pt) * 2004-02-06 2012-04-10 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e inibidores de fosfodiesterase tipo 4 para o tratamento de doenças respiratórias
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
JP4991693B2 (ja) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
US20070065374A1 (en) * 2005-03-16 2007-03-22 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
EP1931338A4 (en) * 2005-09-28 2009-05-27 Merck Frosst Canada Inc AEROSOL POWDER FORMULATION COMPRISING A TAMISED LACTOSE

Also Published As

Publication number Publication date
CR11439A (es) 2010-06-21
US20100210611A1 (en) 2010-08-19
NZ584876A (en) 2012-06-29
MA33705B1 (fr) 2012-11-01
DOP2010000122A (es) 2010-07-15
KR20100072295A (ko) 2010-06-30
EP2211863A1 (en) 2010-08-04
RU2470639C2 (ru) 2012-12-27
WO2009052624A1 (en) 2009-04-30
EP2211863A4 (en) 2012-07-25
IL205182A0 (en) 2010-11-30
JP2011500731A (ja) 2011-01-06
CA2701956A1 (en) 2009-04-30
ZA201002562B (en) 2011-06-29
CO6270213A2 (es) 2011-04-20
WO2009052624A9 (en) 2010-11-25
CN101909626A (zh) 2010-12-08
RU2010120806A (ru) 2011-11-27
AU2008316283A1 (en) 2009-04-30
NI201000069A (es) 2010-08-23
MX2010004529A (es) 2010-05-10

Similar Documents

Publication Publication Date Title
CY2021012I2 (el) Συνθεσεις για αναπνευστικη απελευθερωση ενεργων παραγοντων και συσχετιζομενες μεθοδοι και συστηματα
BR112015029970A2 (pt) inibidores de cinase
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
UA111343C2 (uk) Фармацевтична композиція, що містить мометазону фуроат та азеластину гідрохлорид, для назального введення
MA35616B1 (fr) Compositions pesticides et procédés associés
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
BR112013020650A2 (pt) dispositivo de resseção artroscópica
BR112014030655A2 (pt) inibidores de pirimidinil tirosina quinase
CL2012003450A1 (es) Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
BR112013028474A2 (pt) extrator de tendão do quadríceps
GT200600350A (es) Formulaciones líquidas
GT201000107A (es) Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado.
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
BR112014010633A2 (pt) sistema de controle de odor, dispositivo de disseminação programável e cartucho de controle de odor personalizável
BR112014031372A2 (pt) implantes/procedimentos relacionados ao avanço da tuberosidade tibial
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
MX349802B (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
CO6710916A2 (es) Inhibidores de notum pectinacetilesterasa y métodos de su uso
WO2013155047A3 (en) Compounds and methods for inhibiting cif virulence factor
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
BR112014031664A2 (pt) microcápsula
EA201200855A1 (ru) Модуляторы crth2